Astellas inks neurodegenerative collaboration deal

Share this article:

Astellas continues to expand its list of 2013 partnerships. The drug maker and co-developer Mitokyne announced Monday an R&D agreement to pursue novel drugs that improve mitochondrial functions, with the overall goal being to create drug candidates that could treat genetic, metabolic or neurodegenerative disorders, and even conditions associated with aging. Mitokyne will handle R&D, while Astellas will pick up the clinical development and commercialization side of things.

Monday's announcement is one of a series of recent collaborations, which includes the June R&D agreement with Cytokinetics to target muscle-weakening diseases, May's announcement that it was teaming up with Amgen for cardiovascular and bone diseases, and April's announcement that Astellas and GSK were working on an anemia treatment that dupes the body into thinking it is at a higher altitude to stimulate red blood cell development.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.